Feb 9 Cerus Corp (CERS.O) said it entered into
an agreement with France's national blood transfusion service
to develop its Intercept blood safety system, sending its
shares up about 17 percent before the bell.
Under the agreement, the Etablissement Francais du Sang
(EFS) will co-invest by contributing its facilities, personnel
and resources in support of clinical and commercial product
development, and both CE mark and French regulatory approvals.
EFS has certain royalty rights on future product revenue,
the company added.
Late Monday, the company said the blood system met the main
goal in an early-stage study and the results provided support
to advance into late-stage clinical studies for European
The Intercept system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range
of pathogens that may be present in donated blood.
Shares of the company closed at $2.02 Monday on Nasdaq.
They were trading at $2.35 before the bell.
(Reporting by Jennifer Robin Raj in Bangalore; Editing by